NCT02176850已完成不适用
Safety, Tolerability and Efficacy of Micardis® (Telmisartan) in Patients With Essential Hypertension
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 19,870
- 主要终点
- Indicence of ulcera
研究概览
简要总结
This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis® collected during the clinical studies.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of both sexes with essential hypertension and a minimum age of 18 years
排除标准
- •(Not applicable)
研究组 & 干预措施
Micardis®
干预措施: Micardis® (Drug)
结局指标
主要结局
Indicence of ulcera
时间窗: Up to 6 months after start of study
Incidence of gastrointestinal (GI) bleedings
时间窗: Up to 6 months after start of study
次要结局
- Incidence of adverse events (GI-complaints inclusive)(Up to 6 months after start of study)
- Change from baseline in office blood pressure(Up to 6 months after start of study)
- Response rate(Up to 6 months after start of study)
研究者
相似试验
已完成
不适用
Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With HypertensionHypertensionNCT02242357Boehringer Ingelheim14,553
已完成
不适用
Post-Marketing Surveillance Study of Micardis® Plus in Patients With HypertensionHypertensionNCT02238275Boehringer Ingelheim8,135
已完成
不适用
Micardis®. Observational Study in Patients With Essential HypertensionHypertensionNCT02200094Boehringer Ingelheim4,532
已完成
不适用
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With HypertensionHypertensionNCT02242838Boehringer Ingelheim6,336
已完成
不适用
Micardis® in Patients With Essential HypertensionHypertensionNCT02187705Boehringer Ingelheim1,688